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Abstract 
 
Osteoarthritis is a chronic degenerative disease affecting growing numbers of the 
ageing population. Patients diagnosed with OA place a large burden on access 
to healthcare services, including primary care, prescription of analgesic drugs, 
physiotherapy and joint replacement surgery. Not all patients diagnosed with OA 
will require joint replacement surgery, and therefore avenues for non-surgical 
treatment for such patients needs to be explored in many cases. In this review 
we discuss current concepts underlying the pathophysiology of OA. These form a 
basis to understanding the rationale for new therapies based on recent evidence 
available from clinical trials in OA. In particular, we discuss the evidence for use 
of pharmacological treatments, including NSAIDs (non-steroidal anti-
inflammatory drugs), chondroitin sulphate and glucosamine, hyaluronan, 
potential disease-modifying drugs and other interventions such as weight 
reduction and physiotherapy. Finally, we discuss new developments from trial 
evidence for joint replacement surgery. 
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Osteoarthritis – The burden of disease 
 
 
 Osteoarthritis (OA) is an arthropathy affecting predominantly 
synovial joints that is characterised by cartilage loss and a peri-articular bone 
response (1). In the early stages of disease, cartilage develops irregularities at 
the surface where it becomes fibrillated and appears moderately hypercellular 
(2). As the condition progresses, deep clefts form in the cartilage. There is loss of 
the main components of cartilage matrix which include the proteoglycan 
aggrecan and type II collagen. There is also evidence of cell clumping of 
chondrocytes within cartilage surrounded by regions of intense staining material 
indicating increased proteoglycan production. As ongoing cartilage damage 
occurs, the articular joint surface is damaged, leading to loss of joint function. 
Pathological features observed in the surrounding bone include osteophyte 
formation, bone sclerosis and joint space narrowing. Recently, evidence has 
shown that exacerbations of OA can be associated with a synovial reaction and 
such changes may be amenable to treatment with anti-inflammatory drugs (3, 4, 
5). Clinically, subjects with OA can be divided into a number of subsets. These 
include patients with the following: 
 
1. Nodal generalised OA 
 This is a well-recognised subset, characterised by polyarticular 
interphalangeal joint involvement of the fingers. There is formation of Heberden’s 
nodes (distal interphalangeal joints) and Bouchard’s nodes (proximal 
interphalangeal joints). In addition, this subset has a female preponderance, a 
Clinical trials in Osteoarthritis 
 
 4 
peak onset in middle age, often good functional outcome, predisposition to OA of 
the hip, knee and spine with marked familial predisposition (6). In families with 
hand OA, a greater concordance exists for monozygotic twins than for dizygotic 
twins (7). There is also an increased incidence of hand OA in first degree 
relatives (8). Strategies for treatment of this patient group include 
pharmacological therapies, physiotherapy and risk factor modification. Clinical 
trial evidence of such therapies will be discussed in further detail below. 
 
2. Large-joint OA 
 The knee and the hip are the most commonly affected large joints in 
OA, primarily since they are the main weight-bearing joints in the body. 
Involvement can often be bilateral, although one side is usually more adversely 
affected. OA is a multifactorial disease in which genetic predisposition, age, 
oestrogen status in women and environmental agents all contribute to 
susceptibility. Changes consistent with OA of the hip and knee are often 
confirmed on plain radiography, as shown in Figure 1. Typical features include 
narrowing of the joint space due to loss of cartilage, osteophyte formation, bone 
sclerosis and bone cysts, which are believed to be responses to persistent 
mechanical strain on the joint. 
 In subjects with severe joint space narrowing and loss of function 
e.g. inability to walk reasonable distances with associated pain, several treatment 
modalities may be available. These include treatment of risk factors, analgesic 
therapies, exercise and weight reduction measures. If multidisciplinary 
approaches fail to control pain and loss of function, total joint replacement in the 
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large weight bearing joints with a prosthetic hip or knee, depending on the 
affected joint, is usually considered. Figure 2 shows a femoral head removed at 
the time of surgery from a patient with severe OA of the hip. Much of the pearly 
white appearance of normal cartilage has disappeared and the underlying eroded 
bone is visible (Figure 2).  Disability in OA arises from reduced range of 
movement, diminished control of the affected joint and pain. The pain and 
functional consequences of OA are responsible for the large burden of morbidity 
in the community. Severe knee and hip disease contribute to a large financial 
cost on healthcare services in a generally older and otherwise fitter population. In 
a study by Lawrence et al. (1990), women (but not men) with OA of the knee had 
higher morbidity and cumulative mortality rates between the ages of 55 to 74 (9). 
Increased mortality has also been associated with OA of the knee in Sweden 
(10). To date, apart from joint replacement, few disease modifying therapies exist 
for the treatment of OA. In comparison, inflammatory arthritis e.g. rheumatoid 
arthritis and psoriatic arthritis, can be successfully treated with therapies 
including methotrexate and anti-TNF drugs that inhibit disease progression (11). 
There is therefore a need to gain a better understanding of the disease process 
in OA which could help lead to the development of more effective new 
treatments. 
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Clinical trials Addressing Risk factors for OA 
 
Obesity 
 Obesity is associated with an increased risk of OA, especially at the hip, 
where the risk is higher for women (odds ratio 9.0) than for men (odds ration 4.5) 
(9). Other studies have shown that significant weight reduction can improve the 
pain score and function in subjects with OA (12). Furthermore, a study from the 
Multicenter Osteoarthritis Study reported that obesity was a risk factor for 
incident knee OA (13). In this study, researchers found that disease progression 
was affected by obesity particularly in subgroups of knee OA who had neutral or 
valgus changes, but not varus changes (13). These findings have implications on 
interventions for treating obesity in patients with OA. A recent clinical trial of 289 
patients in the UK utilised an intervention of dietary advice and quadriceps 
exercises delivered to subjects with knee OA, either in combination, or alone 
(14). Primary outcome measures included severity of knee pain as assessed by 
the WOMAC score up to 24 months. The WOMAC (Western Ontario and 
McMaster Universities Osteoarthritis Index) score is one of the most widely used 
and validated assessment for subjects with OA (15). In the same study, 
secondary outcome measures included WOMAC knee physical function and 
stiffness scores and measures for anxiety and depression. The knee quadriceps 
exercise group achieved a significant reduction in pain compared with the non-
exercise group at 24 months (percentage risk difference 11.61 with 95% 
confidence intervals 1.81 to 21.41%). By delivering a reduction in calorific intake 
of 600 kcal per day in the treatment group, the researchers achieved a moderate 
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sustained weight loss which was associated with reduced depression but this 
change did not influence pain or function (14). These results suggest that 
preventing the onset of obesity in the first place may be a better preventative 
measure for developing OA in weight-bearing joints as opposed to delivering 
intervention once patients have established OA in the context of also being 
obese. However, exercise interventions in the obese group of OA subjects 
certainly appear to be beneficial (16). Other studies are currently underway 
investigating the role of intensive treatment by exercise and dietary intervention 
in obese subjects (BMI 27-40.5) with OA, and results of such studies should be 
available over the next few years (17). 
 
Injury 
 Major direct injury to a joint is a predisposing cause of OA such as 
total meniscectomy of the knee (18). Injuries including fractures may also alter 
mechanical loading and predispose to OA at distant sites, as with fractures of the 
femoral shaft (hip OA), scaphoid (wrist OA), tibia (ankle OA) or humerus 
(shoulder OA). Although major direct injuries are predisposing risk factors for OA, 
alone they are usually insufficient to cause OA. This is bourne out by the 
observations that not all subjects who undergo meniscectomy develop OA. 
Subjects who develop OA after direct trauma also have an increased 
predisposition for OA in other joints (18). However, when surgery has been used 
to intervene to treat mensical injuries, this has not always resulted in reduction in 
the progression of OA (19), suggesting that meniscal tears may contribute to 
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disease progression, but that other degenerative processes in the joint persist 
even when meniscal tears are repaired.   
 
Pharmacological therapies for the treatment of pain in OA 
 
This is part of the mainstay of treatment for many cases of OA. Treatment 
with analgesic therapies can be used to treat symptomatic joint pain in OA in a 
variety of regions, ranging from hand, wrist and shoulder to larger weight-bearing 
joints such as the hip and knee. Historically, the convention is to use analgesics 
on the pain ladder, starting with milder agents such as paracetamol, then moving 
on to NSAIDs and opiates until analgesic effect is achieved. Most recent studies 
have focused on newer NSAIDs for the treatment of OA and these agents will be 
discussed in further detail below. Topical therapies including hyaluronan and 
other agents such as glucosamine, chondroitin sulphate and new emerging drugs 
such as anti-NGF therapy will also be discussed in this section. 
 
Non-Steroidal Anti-Inflammatory drugs (NSAIDs) 
NSAIDs are widely used in the treatment of OA and many clinical trials 
have been devoted to studying their effects in patients with this condition. 
NSAIDs have a common mode of action which is to block prostaglandin 
synthesis through the inhibition of cyclo-oxygenase (COX) which catalyses the 
synthesis of prostaglandins and thromboxanes from arachidonic acid. There are 
two isoforms of COX: COX-1 is expressed constitutively in most cell types of the 
body, whereas COX-2 is induced particularly when inflammatory cells are 
activated e.g. by the cytokines IL-1 and TNF and it produces the prostaglandin 
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mediators of inflammation (20). Some of the earliest studies which looked at the 
efficacy of NSAIDs included agents such as phenylbutazone, mefenamic acid 
and indomethacin and many of these studies date back to the early 1970s (21, 
22). Although several of the agents used initially were effective for their analgesic 
properties, they often required high doses and were associated with significant 
side-effects. These included renal, cardiac and gastrointestinal toxicity (23, 24). 
Over recent decades there has therefore been a pressing need to develop 
agents that have an improved efficacy profile with fewer side effects. This has led 
to the emergence of newer agents including diclofenac, naproxen, meloxicam 
and others that have a better efficacy and side effect profile (25).  However, with 
chronic use drugs may accumulate their toxicity and therefore require further 
optimisation to limit their side-effect profile.  These needs have in part led to the 
development of other agents such as COX-II selective agents that include 
etoricoxib and celecoxib that are in clinical use today. These drugs do not appear 
to inhibit COX-1 at clinical doses and are therefore reported to cause fewer 
gastroduodenal ulcers at clinical doses. Compared head-to-head, celecoxib and 
etoricoxib have been shown to be equally effective in improving pain responses 
in subjects with hip or knee OA (26). One of the major issues regarding 
prescription of NSAIDs in this population group, whether they are COX-2 
selective or not, is their gastrointestinal toxicity and cardiovascular side-effect 
profile. A Guideline Development Group working for the National Institute for 
Health and Clinical Excellence recently reported that proton pump inhibitors, 
which are prescribed in patients taking NSAIDs for their gastroprotective effect, 
were cost-effective in patients taking conventional NSAIDs or COX-2 inhibitors at 
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preventing gastroduodenal ulcers (27, 28). More recent trials have focused on 
looking at reducing cardiovascular side-effect profiles in patients with OA taking 
NSAIDs and one of the largest studies of this kind was the MEDAL study (29). A 
meta-analysis of the MEDAL study (Multinational Etoricoxib and Diclofenac 
Arthritis Long-term) found that etoricoxib was associated with a higher incidence 
of hypertension in comparison with diclofenac in patients with arthritis (30). The 
same meta-analysis suggested that treatment of hypertension with calcium-
channel blockers and concurrent NSAID use afforded better control of blood 
pressure in comparison with other anti-hypertensive agents assessed (30). More 
recently, cyclooxygenase inhibiting nitric oxide donators have been used in 
clinical trials to assess effects on blood pressure in patients with arthritis. White 
et al. (2009) reported that over 13 weeks of treatment, naproxcinod did not 
induce as many elevations in blood pressure as in subjects taking naproxen (31). 
Furthermore, the authors suggested that naproxcinod had similar effects to 
placebo on the blood pressure of subjects with OA over the time period studied 
(31). 
 
Hyaluronic acid preparations 
 
Hyaluronan is a normal constituent of the joint which serves functions of 
withstanding load-bearing and forming a large polymeric structure with the main 
proteoglycans in cartilage: aggrecan. It contributes to giving cartilage its 
properties to withstand heavy loads and resist mechanical forces, particularly on 
large weight-bearing joints including the hip and knee. Several clinical trials have 
been conducted in recent years proposing hyaluronic acid preparations as 
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potential treatments for relieving pain in OA. A number of formulations have been 
subjected to clinical trials, including hylan and hyaluronic acid derivatives (32, 33, 
34). Most of the clinical trials have been conducted in subjects with established 
painful knee OA. The usual protocol for most of these studies has been repeated 
injections of hyaluronic acid e.g. series of three injections at weekly intervals. The 
primary outcome measures included assessment of pain and WOMAC (Western 
Ontario and McMaster Universities osteoarthritis index) scores. One of the 
earliest studies by Juni et al. showed an improvement in pain scores in subjects 
given three different forms of hyaluronan (32). Of interest, there were more 
adverse effects in the hyaluronan derived from avian sources in comparison with 
bacterial sources. In this non-industry conducted study, a therapeutic response to 
pain was maintained even at 6 months. More recent studies have included 
placebo arms e.g. with saline treatment to show that the analgesic effect is 
greater in the hyaluronan treated group (34). More recent trials have compared 
hyaluronan head-to-head with corticosteroids to obtain good therapeutic effect  
(35). Furthermore, trials are being reported of efficacy of hyaluronan in smaller 
joints as well e.g. the hand (36). It has also been suggested that repeated 
injections of hyaluronan may be effective (37). 
 
Anti-NGF (nerve growth factor) monoclonal antibodies 
 
Due to the side-effect profile associated with NSAIDs and the need to 
develop alternative therapeutic strategies to treat pain for OA, recent interest has 
focused on NGF (nerve growth factor) as a potential therapeutic target to treat 
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pain. In contrast to TNF, NGF acts primarily through a direct action on sensory 
neurones to induce hyperalgesia (38).  NGF injection into animals or healthy 
volunteers leads to prolonged hyperalgesia and allodynia (39). Increased NGF 
production has been observed from RA and OA synovial cells and chondrocytes 
(40). Lane and colleagues recently reported on a clinical trial of tanezumab, an 
anti-NGF monoclonal antibody as a potential therapeutic target for pain in knee 
OA (41). They reported that repeated doses of 50 µg/kg tanezumab were 
generally safe and well tolerated in patients with knee OA and achieved 
analgesic effect up to 32 weeks. However, the full publication of this study 
including the side-effect profile, are awaited.  
  
Glucosamine 
There is experimental data from in vitro work suggesting that glucosamine 
has chondroprotective effects (42, 43). Various formulations are available, 
including glucosamine hydrochloride and glucosamine sulphate. A number of 
formulations of glucosamine have been in clinical use for many years and the 
early studies of its use date back to the early 1980s (44). It is now widely 
available as an over-the-counter nutritional supplement worldwide. Glucosamine 
has been reported to be efficacious in the oral form to relieve pain severity and 
improve function (45). Reginster et al. (2001) reported that long-term oral 
glucosamine sulphate improved symptoms in older non-obese patients who had 
primary knee osteoarthritis without inflammation (46). In a larger more recent 
study, the effect of glucosamine was compared versus placebo, chondroitin 
sulphate, glucosamine and chondroitin sulphate and celecoxib (47). This clinical 
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trial found that overall, there was little difference between glucosamine and 
placebo: the rate of response to glucosamine was 3.9 percentage points higher 
than placebo (p=0.3), in comparison with celecoxib which was 6.5 percentage 
points higher (p=0.008). A primary response was defined as a 20% decrease in 
the summed score for the pain subscale of the Western Ontario and McMaster 
Universities Osteoarthritis Index (47). Nevertheless, the same study suggested 
that the combination of glucosamine and chondroitin sulphate may be effective in 
a subgroup of patients with moderate-to-severe knee pain (ClinicalTrials.gov 
number, NCT00032890). A Cochrane review on the use of glucosamine has 
reported it is safe and improved pain more frequently than placebo 
(http://www.cochrane.org/reviews/en/ab002946.html). In current clinical practice, 
the use of glucosamine is therefore suggested to be of potential benefit as 
combination therapy with exercise as part of a multidisciplinary programme for 
OA management (48, 49). 
 
Chondroitin sulphate 
Chondroitin sulphate is a sulphated glycosaminoglycan. It is an important 
structural component of cartilage that provides cartilage with its ability to 
withstand compressive loads (50, 51). Chondroitin sulphate, like glucosamine, 
has become widely available as an over-the-counter nutritional supplement for 
use in the treatment of OA. In the USA, chondroitin sulphate is regulated as a 
dietary supplement by the FDA. In Europe, there is an approved formulation of 
chondroitin sulphate which is considered as a reference product, with evidenced 
efficacy and safety demonstrated by clinical trials in osteoarthritic patients. 
Clinical trials in Osteoarthritis 
 
 14 
Adebowale et al. reported in 2000 that of 32 chondroitin supplements they 
analysed, only 5 were labeled correctly, and more than half contained less than 
40% of the labelled amount (52). In the largest clinical trial using chondroitin 
sulphate that has been conducted so far, Clegg et al. reported that in subjects 
with knee OA studied over a 24 week period, the rate of response to chondroitin 
sulphate was 5.3 percentage points higher than placebo (47). Of interest, the 
combination of glucosamine with chondroitin sulphate was 6.5 percentage points 
higher than placebo (p = 0.09). However, the greatest effect on pain 
improvement occurred in the celecoxib group overall with 10.0 percentage point 
rate of response (p = 0.008).  
 
Other Potential Disease-Modifying therapy for Osteoarthritis 
 
 
 Some candidate therapies for disease-modifying drugs in OA have 
surfaced that are reported to inhibit proteolytic enzymes that are implicated in 
cartilage degradation in OA. These drugs include agents which inhibit MMPs 
(matrix metalloproteinases ) and such agents may prevent collagen degradation 
in OA. 
 Work has been previously been conducted using doxycycline in a canine 
cruciate-defieciency model of OA (53). This study showed that reduced levels of 
active and total gelatinase and collagenase were found in extracts of of OA 
cartilage (53). These results have been replicated in human subjects given 
doxycycline undergoing joint replacement surgery (Smith et al. 1998). Other 
agents such as chemically modified tetracycline have been used in a surgically 
induced model of OA in rabbits (54). In the largest study of its kind using 
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doxycycline for potential disease-modifying effect, placebo was compared 
against doxycycline in women with unilateral knee OA. The trial involved 
treatment with doxycycline 100 mg twice daily in the treatment arm or placebo, 
also given twice daily. A total of 431 patients were recruited and showed after 30 
months treatment that doxycycline slowed the rate of joint space narrowing in 
affected knees (55). Of interest, drug intake had no effect on joint space 
narrowing in the contralateral knee, suggesting that other factors may also be at 
play. One limitation of this study was that joint space narrowing was measured 
using plain radiographs, whereas other methods of imaging e.g. MRI may be 
more sensitive at detecting joint space narrowing, or bone marrow oedema, 
which has been implicated in the perception of pain in OA (38, 39). 
 
Conservative Non-Pharmacological Management 
 Increased physical exercise has long been associated with improvement 
in pain and functional outcome in OA (14). However, there is a paucity of 
randomized clinical trials investigating specific interventions for the treatment of 
OA (56, 57). Although there is clear evidence for the use of physiotherapy post-
operatively to improve outcome post joint replacement therapy (58), there are 
only a few studies suggesting the use of exercise as part of a multidisciplinary 
programme in the management of OA (59, 60). In a Cochrane systematic review 
for OA of the knee, land-based exercise was assessed (61). The 32 studies 
included in the analysis up to December 2007 provided data on 3616 participants 
for knee pain and 3719 participants for self-reported physical function. Meta-
analysis showed a beneficial effect of treatment with a standardised mean 
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difference (SMD) of 0.40 (95% confidence interval (CI) 0.30 to 0.50) for pain; and 
SMD 0.37 (95% CI 0.25 to 0.49) for physical function (61). The Cochrane review 
reported platinum level evidence that therapeutic exercise has at least short term 
benefit in terms of reduced knee pain and improved physical function for people 
with knee OA. The magnitude of the treatment effect was considered to be small. 
However, the outcome of physical-based therapies was comparable to estimates 
reported for non-steroidal anti-inflammatory drugs. Exercise invervention for large 
weight-bearing OA of the hip and knee should now therefore be considered as 
part of integrated care for OA (62, 63). Such an integrated rehabilitation package 
has been shown to be an effective and cost-saving method of managing OA 
conservatively (64, 65).  
 
Joint replacement surgery for Osteoarthritis 
 
The surgical options for the treatment of arthritic joints include arthrodesis, 
excision, osteotomy and joint replacement (arthroplasty). In the hip and knee, 
arthroplasty has become the gold standard treatment and as success rates 
continue to increase, so the indications continue to widen. 
 
Total hip replacement 
 
In its present form, popularised by Sir John Charnley in the 1960’s, total 
hip replacement is now well established as one of the most successful modes of 
surgical treatment available in modern healthcare systems (66, 68). Patients can 
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now expect low rates of complications, relatively short hospital stays, rapid return 
to function and longevity of fixation. Techniques and materials sciences have 
been continuously evolving since the 1960’s such that the majority of patients 
now receiving total hip replacement can expect their primary replacement to last 
their lifetime (70).  
 
Much of our improved understanding regarding the survival of arthroplasty 
prostheses is due to the development of arthroplasty registers. The forerunner 
and still world leader in this regard is the Swedish Hip Register. Other large 
registries also exist, including the Norway and Finland Joint Registries (67, 68) 
and more recently the Australian and the UK National Joint Registry  . All 
Orthopaedic surgeons recognize the importance of registry data. The key points 
are that the data reported is surgeon generated, all surgeons should contribute 
so as to avoid bias from inventors and “experts” and the data can be interrogated 
by parties with nothing to gain from the results. In the UK we have seen a 
number of catastrophic implant failures which hopefully will be avoided in the 
future with the advent of a national joint register. Well compiled registry data can 
then be used to generate reports making important statements not only about the 
performance of various implants (68, 69), but also about other aspects of surgical 
technique and surgeon performance. The latter continues to cause concern in 
the surgical population, but as long as case mix is borne in mind, valuable 
information can still be made available both to individual surgeons and to 
institutions. As large joint registers gain in popularity many challenges still exist, 
particularly ensuring completeness of data, maintaining timely responsiveness 
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and keeping the data non-political. Ownership of the data remains one of the 
biggest concerns from a surgical perspective. 
 
Hip replacements comprise of two basic components – femoral and 
acetabular. Broadly speaking, these can be divided into cemented and 
cementless implants. Hip replacements can therefore be cemented, cementless 
or hybrid (a combination of a cemented and a cementless component). Different 
survivorship data are available for each of these types of implants. The gold 
standard hip replacement is still the cemented hip. This is the type of hip that all 
others must be compared to in order to demonstrate equality or superiority. Data 
now exists showing that polished tapered femoral stems implanted with cement 
can survive for more than 30 years (70) . The Achilles heel of the cemented hip 
replacement remains cup fixation, but with modern cup design and cementing 
techniques long-term survival and low wear can be expected. Cementless 
implants gained popularity in the UK and USA as surgeons had concerns about 
cement and it is true that ossoeintegration can be reliably achieved with 
cementless implants (71). Although excellent data now exists regarding 
cementless implants (70), there is no data confirming superiority and these 
implants are associated with higher rates of fracture, stress shielding and thigh 
pain. Generally more expensive, cementless prostheses also place a higher 
burden on health economies than cemented (72).  
 
Fixation to the skeleton, therefore, is no longer a major cause for concern. 
Much more attention has now been focussed on the bearing surface. Until 
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relatively recently the great majority of hip replacements have employed Ultra-
High Molecular Weight Polyethylene (UHMWPE) as the bearing surface and this 
has functioned well. However, as fixation has improved so the need for materials 
with even lower wear rates has increased. Three newer bearing surfaces have 
been employed; cross-linked polyethylene, ceramics and metal on metal, with 
other novel surfaces in development.  
 
Sterilising UHMWPE in gamma-irradiation causes chain scission in the 
long chain molecules and cross-linking. This results in the formation of cross-
linked polyethylene and the amount of cross-linking is dependant upon the dose 
of radiation used. Cross-linked polyethylene has been used in hip replacement 
prostheses for more than 10 years and very low wear rates have been observed 
(73, 74). It is important that the cross-linking is performed in an inert environment 
so as to avoid oxidation which weakens the substrate and to remove any free 
radicals present at the end of sterilisation so as to limit the amount of oxidation 
that may occur in vivo. Concern also persists about the functional biological 
activity of any wear particles produced, but this has not yet been confirmed. Third 
generation cross-linked polyethylenes are now available which retain the 
mechanical properties of traditional UHMWPE, have extremely low wear rates 
and which are very much less vulnerable to oxidation processes. With lower wear 
rates, so the polyethylene can be made available in thinner implants so allowing 
for larger femoral head size with a greater range of motion and stability. 
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Ceramics have been available for many years as a bearing surface for hip 
replacements. Ceramics are extremely hard, well lubricated in the body and 
demonstrate extremely low wear rates. Difficulty in manufacture, expense and 
vulnerability to material fracture have limited success until relatively recently. 
Processes involving high temperature and pressure (HIP) optimises the material 
properties of ceramic femoral heads and acetabular liners. Risk of fracture is 
minimized due to a high density of consistently sized particles and additives such 
as platelets in certain processes. Large head bearing couples are facilitated and 
the wear rates with modern ceramics are so low, producing inert particles, so that 
the lifetime of a hip replacement will not be limited (77). Ceramics have not 
gained universal popularity, however, largely because of expense, persisting 
concern about fracture and concerns regarding squeaking (75, 76). Due to a 
combination of transient loss of lubrication, separation of components during gait 
and unusual forms of surface wear, a significant minority of patients with ceramic 
bearing surfaces report squeaking during various activities of daily living and this 
can be a cause for revision surgery in an otherwise well functioning hip 
replacement. 
 
Ceramic on ceramic 
Developed in the 1970’s the Mackee-Farrar Hip Replacement 
demonstrated that extremely low wear rates can be achieved using metal-on-
metal articulations (MOM). With accurate machining and appropriate tolerances 
long-term survival can be expected. MOM bearings can be produced in a 
relatively non-expensive method and large head couples are facilitated. The 
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major concern regarding MOM bearings is the biological activity of the wear 
particles produced. MOM bearings produce a very large number of sub-micron 
particles, particularly during the “running-in” period (78). Rate of production also 
varies with implantation technique, implant size and patient activity level. The 
metal wear particles are biologically active and can excite a local response which 
can be highly damaging to the tissues (ALVAL). Although not proven concerns 
also exist regarding propensity to tumour initiation and teratogenic risk. 
 
Hip Resurfacing 
As MOM bearings have regained popularity so interest has moved 
towards “conservative” hip replacement. Fundamental to this philosophy is the 
tenet that when revision surgery becomes necessary so more bone is available 
as less has been violated at the primary procedure. Hip Resurfacing has gained 
popularity in the UK during the last 10 years and has been termed the “high 
performance” hip amongst other terms. However as concerns regarding MOM 
bearings have increased (79), particularly local responses such as ALVAL so the 
popularity of hip resurfacing has dwindled. Femoral neck fracture and loosening 
have also been reported in certain groups of patients and with certain brands of 
implants. Hip resurfacing remains a successful implant in relatively young males 
with normal anatomy, but in other patient groups popularity with surgeons has 
reduced dramatically. Even in the young male group there is no demonstrable 
superiority in terms of function or longevity when compared to traditional hip 
replacements (80). Other conservative hip replacements are in development, but 
at this stage must be regarded as experimental. 
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Total Knee Replacement 
 
The results of total knee replacement continue to be less good and less 
predictable than total hip replacement. Approximately 5% of patients have worse 
pain following “successful” total knee replacement than prior to surgery and the 
mechanisms for this are poorly understood. Current research is on-going to try 
and understand this better and psychological and socio-economic reasons may 
contribute as well as technical aspects of surgery. 
 
There are many aspects of total knee replacement under investigation but 
none of them as yet have shown a definite advantage over the condylar, 
cemented “gold standard” total knee replacement16. Patellar resurfacing versus 
non-resurfacing, posterior cruciate retaining versus sacrificing knee replacement, 
fixed bearing versus mobile bearing (81), anatomical versus alternative 
geometry, cemented versus cementless fixation, highly crosslinked polyethylene 
and novel materials such as trabecular metal are all under evaluation, but 
persuasive, definitive trials are as yet elusive.  
 
Computer navigation may have a role to play in total knee replacement. 
Traditional implantation methods employ intra-medullary and extra-medullary 
alignment rods which are unreliable and risk fat embolism. Use of computer 
navigation techniques avoid these rods, thus greatly reducing the risk of Fat 
embolism syndrome and implantation can be performed with a higher degree of 
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accuracy and reproducibility. As yet, however there has been little if any 
convincing evidence of clinical benefit to what is a very expensive system (82). 
 
Unicompartmental knee replacement 
The treatment of isolated compartment arthritis remains controversial. 
Medial compartment arthritis and patello-femoral arthritis can now be 
successfully treated with uni-compartment replacements and lateral compartment 
replacement is growing in popularity. These procedures rely on intact ligaments 
and near normal anatomy and are truly bone preserving when performed 
appropriately. Mobile bearing medial uni-compartment replacement can be 
associated with extremely good post-operative scores, probably better than the 
same group of patients receiving total knee replacements and longevity may be 
also as good (83).  
 
Common to both total hip replacement and total knee replacement has 
been tremendous improvements in anaesthetic, nursing and rehabilitation 
techniques. High volume centres employing regional anaesthetic techniques with 
early discharge planning can achieve lengths of stay of 1 to 5 days following joint 
replacement (84) and this in the authors view has been the major advance in 
joint replacement surgery over the last 5 years. Regional anaesthetic techniques 
allow patients to recover with minimal pain and the incidence of thrombo-embolic 
complications and blood transfusion is also lower. In the early 21st Century, then, 
patients can expect minimal pain and a short stay following joint replacement, a 
major complication rate of approximately 1% and a hip replacement that will 
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function well for perhaps 30 years and a knee replacement for perhaps 15 (85) 
years. Further research will bring about only relatively small incremental change. 
The danger of ill-conceived innovation is recognised mainly through the Joint 
Registers and very long term follow up studies are now needed to illustrate 
differences between implants and techniques. 
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Figure 1. 
Panel A. Normal knee joint demonstrated on radiography with even and smooth 
joint space 
Panel B. Joint space narrowing at medial aspect of femoro-tibial knee joint from a 
patient with osteoarthritis (indicated by arrow) 
 
 
 
 
 
 
 
 
 
A. Normal knee B. OA knee
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Figure 2. Joint replacement surgery for osteoarthritis 
 
A. Macroscopic appearance of a hip joint from a patient undergoing joint 
replacement surger. The femoral head removed at the time of hip joint 
replacement surgery from a patient with severe OA shows destruction of the 
articular cartilage. The normal pearly white appearance has disappeared to be 
replaced by denuded cartilage that reveals underlying bone. 
B. A prosthetic right hip is demonstrated in situ post hip arthroplasty 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. B.
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